Axovant ’s Phase III trial of Alzheimer's disease drug fails to meet primary endpoints
Axovant Sciences has reported negative top-line results from its Phase III MINDSET clinical trial of intepirdine conducted to treat mild-to-moderate Alzheimer's disease (AD).
Sven van der Lee is a medical doctor and postdoctoral researcher at the Alzheimer Center, VU University Medical Center (Amsterdam, Netherlands). He earned his MD at Leiden University Medical Center (Leiden, Netherlands), is trained as a genetic epidemiologist, and obtained his PhD at Erasmus Medical Center (Rotterdam, Netherlands). In his research he identified, in large scale collaborative analyses, multiple genetic and metabolic factors that influence the risk of Alzheimer's disease. He is particularly interested in the translation of findings from basic science to clinically useful markers of dementia.
Risks of dementia and Alzheimer's disease reflect the combined effects of age, genetic variants, and social and behavioural determinants.1 In The Lancet Neurology, Sven van der Lee and colleagues2 use data from the Rotterdam Study to address the important task of predicting whether an individual is likely to develop Alzheimer's disease or dementia in his or her lifetime. In this cohort, a genetic risk score (GRS) of 23 genetic variants modified the risk of late-onset Alzheimer's disease or dementia above and beyond the effect of the gene for apolipoprotein E (APOE).
Conclusions: Patients with bvFTD require a high intensity of emotional stimulus and are significantly hyporesponsive to low-intensity stimuli. Simple screening or observations of verbal and facial responsiveness to mildly arousing stimuli may aid in differentiating bvFTD from normal subjects and patients with other dementias. Future studies can investigate whether delivering information with high emotional intensity can facilitate communication with patients with bvFTD. PMID: 29686739 [PubMed - in process]
We present “Attic” programs at six facilities each month which engage ninety seniors. David and Lynda will be presenting about their outreach services in a webinar on Friday, April 27th, Grab and Go: Expanding and Strengthening Senior Programming
Dr Vega discusses a study exploring a possible link between Alzheimer dementia and daytime sleepiness.Medscape Internal Medicine
Dr Vega discusses a study exploring a possible link between Alzheimer dementia and daytime sleepiness.
The first population study of sense of smell and cognitive performance by age suggests that testing sense of smell could be a marker for cognitive decline.
Hydrogen-rich water improves cognitive impairment gender-dependently in APP/PS1 mice without affecting Aβ clearance. Free Radic Res. 2018 Apr 23;:1-12 Authors: Hou C, Peng Y, Qin C, Fan F, Liu J, Long J Abstract Alzheimer's disease (AD) is characterised as a provoked inflammatory response and oxidative stress along with amyloid β peptide (Aβ) deposition and neurofibrillary tangles in the brain, and effective treatment is greatly needed. Molecular hydrogen, which has been proposed to be an antioxidant that selectively reduces reactive oxygen species, was found to exert beneficial effects ...
Authors: Tchalla AE, Clément JP, Saulnier I, Beaumatin B, Lachal F, Gayot C, Bosetti A, Desormais I, Perrochon A, Preux PM, Couratier P, Dantoine T Abstract BACKGROUND/AIMS: Alzheimer disease (AD) is particularly devastating, with no cure, no means of prevention, and no proven way to slow progression. AD is associated with the worsening of cognitive function attributable to a variety of factors of which little is known. Our main objective was to determine factors associated with rapid cognitive decline (RCD) in older AD patients. METHODS: We conducted a 12-month, prospective, multi-centre cohort study. C...
Authors: Goldman DP, Fillit H, Neumann P Abstract In June 2017, a diverse group of experts in Alzheimer's disease convened to discuss how to accelerate getting new drugs to patients to both prevent and treat the disease. Participants concluded that we need a more robust, diversified drug development pipeline. Strategic policy measures can help keep new Alzheimer's disease therapies (whether to treat symptoms, prevent onset, or cure) affordable for patients while supporting innovation and facilitating greater information sharing among payers, providers, researchers, and the public, including a postmarket surveillanc...